News
Merck announced Monday it will acquire U.S. biotech company SpringWorks Therapeutics for $47 per share in cash, valuing the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback